Closing of Second Antibiotic Company Highlights Urgent Need for Investment in Infection Fighting Drugs

The bankruptcy announced today by antibiotic maker Melinta once again highlights the daunting challenges facing research and development of new infection-fighting drugs. Melinta is the second antibiotic company this year forced into bankruptcy because it could not make a sufficient return on its investment in medicines that are urgently needed to protect individual and public health and national security. Melinta’s bankruptcy puts into jeopardy the continued availability of its four antibiotics — lifesaving tools that patients cannot afford to lose given our already limited antibiotic arsenal.

Read more

Flu Preparedness Hearing Opens Opportunities for Vaccine, AMR Action

Today’s subcommittee hearing on U.S. preparedness and responses for the 2019-2020 flu season offers an important opportunity to examine and act on gaps and challenges exacerbating the public health threats of seasonal influenza outbreaks.

Read more